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Thorleif Etgen1,2Abstract
Chronic kidney disease (CKD) has evolved as a possible new determinant of cognitive decline and dementia. This
review outlines the presumed pathophysiology of cognitive decline in CKD, which consists of traditional and new
vascular risk factors as well as nonvascular risk factors and metabolic and biochemical abnormalities within the
central nervous system caused by CKD. The recent major cross-sectional studies and longitudinal studies – including
one meta-analysis – that mostly suggest an association of cognitive decline and CKD are discussed. Finally, potential
therapeutic strategies are presented.Introduction
Cognitive decline comprising cognitive impairment and
dementia is of increasing interest due to a worldwide
ageing population with, on the one hand, a rising inci-
dence of cognitive decline and, on the other, limited
therapeutic options. The potential for primary prevention
of dementia has been thoroughly studied and possibly
one-third of Alzheimer’s dementia cases might be attribut-
able to potentially modifiable risk factors [1]. The concept
of mild cognitive impairment, which describes cognitive
impairment beyond that of normal ageing but in contrast
to dementia, does not interfere notably with activities of
daily life [2], permits timely identification of patients at
high risk of developing dementia and implies the potential
of a larger therapeutic window for modifiable risk factors
[3]. Among these somatic risk factors, chronic kidney dis-
ease (CKD) has been discussed as a potential independent
risk factor for cognitive decline [4,5].
The aims of this review are to summarize the anatomical
and neuroimaging background and pathophysiology of
cognitive decline in CKD, to provide an updated overview
of the major clinical studies of the association between
CKD and cognitive decline, and to indicate possible thera-
peutic strategies.Correspondence: thorleif.etgen@kbo.de
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unless otherwise stated.Anatomical and neuroimaging background
The kidney and the brain possess a similar low vascular
resistance system allowing continuous high-volume per-
fusion, which makes both organs vulnerable to micro-
vascular injury caused by hypertension and diabetes [6].
The resulting small-vessel disease manifests in both
organs: in the brain, it leads to white matter lesions that
contribute to cognitive decline; and in the kidney, it is
characterized by glomerular endothelial dysfunction and
lipohyalinosis accounting for CKD [7].
This anatomical analogy is supported by neuroimaging
results demonstrating that individuals with lower esti-
mated glomerular filtration rate (eGFR) have a greater
volume of white matter lesions, more silent brain infarcts
and cerebral microbleeds [7]. According to one recent
longitudinal study, however, CKD is associated with de-
mentia even independent of cerebral small-vessel disease
[8]. In this Japanese study with 600 older participants,
CKD at baseline was associated with an increased risk of
all-cause dementia during a mean follow-up of more than
7 years and after adjusting for magnetic resonance im-
aging findings and confounding variables (hazard ratio
1.96, 95% confidence interval (CI) 1.08 to 3.58). Magnetic
resonance imaging findings included cerebral atrophy
(medial temporal lobe atrophy or bicaudate ratio indica-
tion subcortical atrophy) and small-vessel disease (repre-
sented by lacunar infarction or white matter lesions) [8].an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Traditional vascular risk factors such as hypertension,
diabetes mellitus, hyperlipidemia, cigarette smoking and
cardiovascular disease with myocardial infarction and
atrial fibrillation have been linked to cognitive decline in
patients with CKD [5] (Figure 1).
Nontraditional vascular risk factors including hyperho-
mocysteinemia, hemostatic abnormalities or hypercoagu-
able states, inflammation and oxidative stress are also
associated with cognitive impairment in patients with
renal failure [4]. Possible mechanisms comprise direct
prothrombotic effects on the vascular system leading to
large-vessel and small-vessel disease. Furthermore, endo-
thelial dysfunction mediated by hyperhomocysteinemia
is associated with ischemic leukoaraiosis [9]. Finally, hy-
perhomocysteinemia has a direct neurotoxicity through
overstimulation of N-methyl-D-aspartate receptors [10].
In addition, nonvascular risk factors might further con-
tribute to cognitive decline in patients with CKD. Anemia
in CKD has been associated with cognitive impairment,
and treatment of anemia showed a progressive effect on
improving cognitive function in CKD patients [11].
Multiple medications are required in CKD patients and
the optimal dosing of several medications is unclear;
these patients are therefore more susceptible to side
effects and interactions between medications [5]. Sleep
disturbances are frequent in patients with end-stage
CKD, resulting in impaired concentration, excessive
daytime fatigue and possibly cognitive dysfunction [12].
Finally, multifactorial metabolic and biochemical ab-
normalities within the central nervous system in renal
failure might further account for cognitive impairment.
Secondary hyperparathyroidism leading to an increasedFigure 1 Pathophysiology of cognitive decline in patients with chroncalcium uptake impairs metabolism of neurotransmitters
such as brain gamma-aminobutyric acid, norepinephrine
and acetylcholine [13]. Amino acid derangements (mainly
glutamine, glycine, aromatic and branched-chain amino
acids) leading to subsequent imbalance of neurotransmit-
ters – mainly gamma-aminobutyric acid, dopamine and
serotonin – contribute to cognitive impairment [14].
Uremic toxins such as guanidine compounds (creatinine,
guanidine, and so forth) also have a neurotoxic effect by
activation of N-methyl-D-aspartate receptors and concomi-
tant inhibition of gamma-aminobutyric acid receptors [15].
Overview of major studies
Cross-sectional studies
The majority of larger cross-sectional studies reported
an increased risk of cognitive decline in the presence of
CKD. The Heart Estrogen/Progestin Replacement Study
examined 1,015 older women with established coronary
artery disease and found an approximately 15 to 25%
increase in risk for global cognition, executive function,
language and memory per 10 ml/minute/1.73 m2 decre-
ment in eGFR [16]. The Third National Health and
Nutrition Examination Survey observed poorer learning/
concentration (odds ratio (OR) 2.4, 95% CI 1.3 to 5.6)
and impairment in visual attention (OR 2.7, 95% CI 1.0
to 7.4) in association with moderate CKD (eGFR 30 to
59 ml/minute/1.73 m2) among 4,849 young, healthy,
ethnically diverse participants [17]. The Reasons for
Geographic and Racial Differences in Stroke Study
reported for patients with CKD among 23,405 partici-
pants that each 10 ml/minute/1.73 m2 decrease in eGFR
was associated with an 11% increased prevalence of cog-
nitive impairment (OR 1.1, 95% CI 1.0 to 1.2) [18]. The
Maine-Syracuse Longitudinal Study noticed among 923ic kidney disease.
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and specific cognitive functions were negatively affected
early in CKD [19].
The Chronic Renal Insufficiency Cohort study con-
tributed two analyses. Using six different cognitive
tests, the first substudy with 825 participants (mean age
65 years) reported participants with advanced CKD
(eGFR <30 ml/minute/1.73 m2) were, after multiple
adjustment, more likely to have clinically significant
cognitive impairment on global cognition (OR 2.0, 95%
CI 1.1 to 3.9), naming (OR 1.9, 95% CI 1.0 to 3.3),
attention (OR 2.4, 95% CI 1.3 to 4.5), executive function
(OR 2.5, 95% CI 1.9 to 4.4) and delayed memory (OR 1.5,
95% CI 0.9 to 2.6) compared with those with mild to mod-
erate CKD (eGFR 45 to 59 ml/minute/1.73 m2) [20]. The
main Chronic Renal Insufficiency Cohort study found
among 3,591 participants a higher prevalence of cognitive
impairment in those with lower eGFR (OR 1.5, 95% CI 1.1
to 2.1), independent of traditional vascular risk factors.
However, this association was no longer significant after
adjustment for hemoglobin concentration [21].
Longitudinal studies
The majority of recent prospective studies found an
association between CKD and cognitive decline (Table 1).
The Cardiovascular Health Cognition Study reported
that an increase in creatinine from 1.0 to 2.0 mg/dl was
associated with a 26% increased risk of vascular-type
dementia [22]. The Health, Aging, and Body Compos-
ition Study demonstrated that more advanced stages of
CKD were associated with an increased risk for cognitive
impairment [23]. The German Intervention Project on
Cerebrovascular Diseases and Dementia in the Commu-
nity of Ebersberg study found that moderate-to-severe
impaired renal function was associated with incident
cognitive impairment after 2 years in a large cohort of
older subjects [24]. In the Northern Manhattan Study,
decreased kidney function estimated by two different
formulas was associated with greater cognitive decline,
even in those with mild CKD [25]. The Rush Memory
and Aging Project indicated that impaired baseline
kidney function was associated with a more rapid rate of
cognitive decline, especially in semantic, episodic and
working memory, but not in visuospatial abilities or
perceptual speed [26]. The Osaki-Tajiri Project from
Japan showed CKD to be strongly associated with
incident dementia even after multiple adjustments for
cardiovascular risk factors including anemia [27]. The
Maine-Syracuse Longitudinal Study observed a decline
in eGFR values being associated with a decline in global
cognitive ability, verbal episodic memory and abstract
reasoning over time [28]. The Cardiovascular Health
Study demonstrated a higher risk of worsening cognitive
function in older adults with lower kidney function [29].However, some studies reported nonsignificant or only
partial significant results. The Osteoporotic Fractures in
Men Study found an independent association between
mild-to-moderate impaired renal function and poor
executive function at baseline but not with global cogni-
tive impairment or risk of cognitive decline in older men
[30]. The Rancho Bernardo study yielded an association
between reduced cognitive function at follow-up only
for baseline albuminuria and only for men, but neither
for women nor for baseline eGFR [31]. In the French
Three C study, no increased risk of cognitive decline or
dementia was associated with low eGFR level, although
faster decline of renal function was associated with
global cognitive decline and incident dementia with vas-
cular component [32]. The Reasons for Geographic and
Racial Differences in Stroke study reported that an
impaired eGFR was not associated independently with
cognitive impairment if compared with preserved eGFR
unless albuminuria was added to the stratification [33].
Meta-analysis
One meta-analysis explored the impact of CKD on cog-
nitive decline. Six cross-sectional studies and six longi-
tudinal studies comprising 54,779 participants could be
included in this meta-analysis. Concerning cross-sectional
studies, meta-analytic pooling using a random-effects
model showed that participants with CKD had a signifi-
cantly increased risk of cognitive impairment compared
with those without CKD (OR 1.65, 95% CI 1.32 to 2.05).
Among longitudinal studies, participants with CKD had
a significantly increased risk of incident cognitive im-
pairment at follow-up compared with those without
CKD (OR 1.39, 95% CI 1.15 to 1.68). Both meta-analyses
comprised a significant heterogeneity amongst the studies
(degrees of freedom= 9, P = 0.0005 and degrees of free-
dom = 11, P <0.0001, respectively) [34]. The association of
patients with CKD having a significantly increased risk of
cognitive impairment compared with those without CKD
remained present independent of the stage of CKD, and
was even stronger in the group with moderate-to-severe
CKD (GFR <45 ml/minute/1.73 m2) compared with mild-
to-moderate CKD (GFR 45 to 60 ml/minute/1.73 m2).
Further sensitivity analyses by grouping studies according
to various characteristics such as sample size of the study
populations, duration of follow-up and method used to
evaluate cognitive function yielded no significant differ-
ences across studies [34].
Limitations
As pointed out in recent reviews, methodological problems
of both cross-sectional studies and longitudinal studies
limit their interpretation and may also explain divergent
results [34,35]. Methods for assessing cognitive function
showed great variability, ranging from the 6-Item Cognitive





Cognitive test Assessment (1) and
classification (2) of
renal function
Adjustment for confounders Result (risk for cognitive decline
depending on renal function/
proteinuria/albuminuria)
Osteoporotic Fractures
in Men Study [30]
5,929 men 74 5 3MS, Trails B (1) MDRD Age, education, race, health status,
ADL impairment, alcohol, diabetes,
hypertension, CHD, stroke, BMI, PAD
Not significant for both
tests in both CKD groups
(2) Mild CKD = eGFR
45 to 59, moderate
CKD = eGFR <45
Rancho Bernardo
Study [31]
1,345 75 6.6 MMSE, Trails B,
Category Fluency Test
(1) MDRD Age, hypertension, HbA1c,
dyslipidemia, education, exercise,
alcohol, estrogen, depression
Not significant for eGFR
(2) Moderate-to-severe
CKD = eGFR <60
Significant only for men
and baseline albuminuria
Three C Study [32] 7,839 74 7 MMSE (1) CKD-EPI Age, sex, education, ApoE,
hypertension, CHD, dyslipidemia,
diabetes, smoking, BMI, stroke
Not significant except for
eGFR decline over first 4 years
and vascular dementia




19,399 64 3.8 6-Item Screener (1) CKD-EPI Age, sex, race, education, region,
hypertension, diabetes, stroke,
CHD, alcohol, smoking
Not significant for eGFR <60
(2) CKD = eGFR <60 OR 1.30 (95% CI 1.02 to 1.66) for
UACR <10 mg/g in eGFR <60
Cardiovascular Health
Cognition Study [22]
3,349 77 6 Cognitive battery
testing for dementia
similar to DSM-IV criteria
(1) Inverse of creatinine Age, sex, race, body weight,
education, CHD, stroke, hypertension,
diabetes, smoking, apoE genotype
37% increased risk of dementia
(95% CI 1.06 to 1.78)
(2) Moderate CKD = SCr
≥1.3 mg/dl for women
and ≥1.5 for men
Health, Aging, and Body
Composition Study [23]




OR 1.32 (95% CI 1.03 to
1.69) for eGFR 45 to 59
(2) CKD = eGFR <60
with two subgroups
(eGFR 45 to 59 and <45)
OR 2.43 (95% CI 1.38 to
4.29) for eGFR <45
INVADE study [24] 3,697 68 2 6-Item Cognitive
Impairment Test




Moderate-to severe CKD: OR
2.14 (95% CI 1.18 to 3.87)
(2) Mild CKD = eGFR
45 to 59, moderate-to-













Table 1 Major longitudinal studies about the association of chronic kidney disease and cognitive decline (modified after [34]) (Continued)
Rush and Memory
Aging Project [26]
886 81 3.4 Battery of 19 tests with
five cognitive systems
(1) MDRD at baseline Age, sex, education, BMI,
hemoglobin, physical activity,
social activity, hypertension,
diabetes, smoking, CHD, stroke,
PAD, depression
Each GFR reduction of
15 = increased rate of
global cognitive decline
of being 3 years older
(2) CKD = eGFR <60
Northern Manhattan
Study [25]





Decline by 0.3 TICS
points/year for eGFR <60
(2) Mildly reduced renal
function = eGFR 60 to 90,
eGFR <60
Decline by 0.2 TICS points/
year for eGFR = 60 to 90
Osaka-Tajiri Project [27] 497 74 5 Clinical Dementia
Rating
(1) Not described Age, sex, education, hypertension,
diabetes, dyslipidemia, CHD, anemia
Conversion to dementia
OR 5.3 (95% CI 1.7 to 16.2)




590 62 5 Composite scores of
VM, VSOM, ST and WM
(1) MDRD Age, sex, education, race,
diabetes, BMI, smoking, HDL
cholesterol, hypertension
Global cognitive ability:
b = 0.21 SD decline/unit
ln(eGFR) (95% CI 0.04 to 0.38)
(2) CKD = eGFR <60 Verbal episodic memory:
b = 0.28 SD decline per unit ln
(eGFR) (95% CI 0.02 to 0.54)
Abstract reasoning: b = 0.36
SD decline per unit ln(eGFR)
(95% CI 0.04 to 0.67)
Cardiovascular
Health Study [29]





(2) CKD = eGFR <60 OR 0.64 (95% CI 0.51
to 0.77) in 3MS
OR 0.42 (95% CI 0.28
to 0.56) in DSST
Osaka Follow-up Study for
Carotid Atherosclerosis,
Part 2 [8]
600 68 7.5 MMSE (1) MDRD Age, sex, ApoE, education,
hypertension, diabetes,
cerebrovascular events
HR 1.96 (95% CI 1.08
to 3.58)
(2) CKD = eGFR <60 brain atrophy, SVD
ADL, activities of daily living; ApoE, apolipoprotein E genotype; BMI, body mass index; CG, Cockcroft–Gault equation; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration equation; CRP, C-reactive protein; DSST, Digit Symbol Substitution Test; eGFR, estimated glomerular filtration rate (ml/minute/1.73 m2); HDL, high-density lipoprotein; HR,
hazard ratio; INVADE, Intervention Project on Cerebrovascular Diseases and Dementia in the Community of Ebersberg; 3MS, Modified Mini-Mental State Examination; MDRD, Modification of Diet in Renal Disease; MMSE,
Mini-Mental State Examination; OR, odds ratio; PAD, peripheral artery disease; SCr, serum creatinine; SD, standard deviation; ST, scanning and tracking; SVD, small-vessel disease; TICS, telephone interview for cognitive
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Mental Status Examination [21,23,32] to a battery of
multidomain cognitive tests [16,19,26]. The study popula-
tion varied from gender specific – for example, women
with coronary heart disease [16] or men [30] – to
community-dwelling participants [24]. The mean age of the
study population ranged from 36 years [17] to 81 years
[26]. Different methods of assessing CKD were applied (for
example, Modification of Diet in Renal Disease equation,
Cockcroft–Gault equation, CKD Epidemiology Collabor-
ation equation, cystatin-based eGFR). The more sensitive
method of albuminuria was seldom applied. The extent of
potential confounders ranged from only a few confounding
factors to many, including recent confounders such as
physical activity, depression or apolipoprotein E [35].
Conclusions and future directions
Data from pathophysiology, anatomy and neuroimaging
studies provide substantial background for the hypothesis
of an independent association between CKD and cognitive
decline, which is further underlined by the results of most
cross-sectional and longitudinal studies including one
meta-analysis. Therapeutic strategies will account for the
different risk factors, but only few intervention trials have
been performed. For example, treatment of hyperhomo-
cysteinemia with high daily doses of B vitamins did not
affect cognitive outcomes after 1 year in a randomized
placebo-controlled trial of 659 advanced CKD patients
[36], but it remains unclear whether a substitution in early
CKD might be beneficial.
Improving renal anemia by erythropoietin could improve
cognitive function, but one double-blind randomized trial
of darbepoetin in CKD patients with moderate anemia did
not specifically assess cognitive function. Furthermore, dar-
bepoetin did not reduce the major outcome (risk of death,
cardiovascular event or renal event) and was associated
with an increased risk of stroke, which is a risk factor for
dementia [37]. Successful kidney transplantation yielded
long-term improvement in the cognitive performance of
patients on chronic dialysis [38].
Whether maintaining blood pressure levels lower than
current recommendations further reduces the risk of age-
related cognitive decline in patients with and without CKD
is currently being investigated in one ongoing large trial
(Systolic Blood Pressure Intervention Trial) [39]. Further
research and intervention strategies are required and will
help to explore the association of cognitive decline in CKD.Note: This article is part of a series on The impact of acute and
chronic medical disorders on accelerated cognitive decline, edited
by Carol Brayne and Daniel Davis. Other articles in this series can
be found at http://alres.com/series/medicaldisordersAbbreviations
CI: Confidence interval; CKD: Chronic kidney disease; eGFR: Estimated
glomerular filtration rate; OR: Odds ratio.Competing interests
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